Dan Kitwood/Getty
- An experimental drug to treat Alzheimer's disease just failed a late-stage trial.
- VTV Therapeutics, a small company in North Carolina, was developing an Alzheimer's drug azeliragon to inhibit the RAGE receptor, ideally to help people with mild Alzheimer's delay cognitive decline.
- Its phase 3 trial wrapped up in early 2018, but the treatment, when compared to placebo, "did not improve in cognitive or functional outcomes." The company is discontinuing its clinical trials.
- "We will continue to analyze the datasets and trends within subgroups from both Part A and Part B to determine if there are potential benefits or future uses and applications for azeliragon," VTV CEO Steve Holcombe said in a news release Monday.
NOW WATCH: There's a surprising twist at the end of the 'synchronized global growth' story
See Also:
- Jamie Dimon set out how his new venture with Amazon and Berkshire Hathaway plans to tackle some of healthcare’s biggest problems
- An investor whose firm has raised $1.8 billion to invest in biotech explains why we're seeing so many huge early funding rounds
- A small but growing movement of doctors that don't accept insurance and charge a monthly fee could be a model for big employers like Amazon and JPMorgan
